Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349).
April C PettitPatrick Pj PhillipsEkaterina KurbatovaAndrew VernonPayam NahidRodney DawsonKelly E DooleyIan SanneZiyaad WajaLerato MohapiAnthony T PodanyWadzanai SamanekaRada M SavicJohn L JohnsonGrace MuzanyiUmesh G LallooKia BryantErin SizemoreNigel ScottSusan E DormanRichard E ChaissonSusan Swindellsnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
In people with HIV-associated DS-PTB with CD4 + counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was non-inferior to the 6-month control regimen and was safe.
Keyphrases
- antiretroviral therapy
- hiv infected
- pulmonary tuberculosis
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- hiv testing
- mycobacterium tuberculosis
- induced apoptosis
- hepatitis c virus
- men who have sex with men
- cell cycle arrest
- physical activity
- cell death
- peripheral blood
- signaling pathway
- cell proliferation
- nk cells